Research
Two compounds target drug-resistant brain cancer cells in laboratory tests
The Brief
- Two compounds were tested in laboratory experiments against drug-resistant brain cancer cells.
- The source describes brain cancer as causing more than 300,000 new cases each year worldwide, with glioblastoma as an aggressive form.
- The results come from laboratory tests only, so effects in patients have not been shown.
Why it matters
Drug resistance is a central obstacle in treating aggressive brain tumours, so compounds that act on resistant cells are worth tracking, though lab results often do not carry over to patients.
Who’s affected
- Patients with drug-resistant brain cancer such as glioblastoma
- #brain cancer
- #glioblastoma
- #drug resistance
- #cancer research
- #laboratory studies
Cancer remains among the most deadly diseases worldwide. Globally, more than 300,000 new cases of brain cancer are reported each year, with glioblastoma, an aggressive form of brain cancer, accounting for over 250,000 deaths. The current standard of care involves the use of…